If red light therapy is able to inhibit the age-dependent RGC degeneration and visual impairment in Opa1+/− mice, it may have potential as a future treatment for ADOA and other optic neuropathies involving RGC pathology. The gene discussed is OPA1; the disease is Optic neuropathy.